Introduction {#sec1}
============

In December 2019, a series of pneumonia cases of unknown origin were identified in Wuhan, China.[@bib1] The pathogen has since been identified as a novel enveloped RNA betacoronavirus that has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[@bib2] The first confirmed case of coronavirus disease 2019 (COVID-19) in the United States was reported in Washington State in January 2020.[@bib3] Although the typical presentation involves viral pneumonia causing severe respiratory deterioration, a hypercoagulable state has been observed in many patients with SARS-CoV-2, and is a predictor of a worse prognosis.[@bib1] ^,^ [@bib4], [@bib5]

COVID-19 may predispose to both arterial and venous thromboembolic complications.[@bib6] The cumulative incidence of thrombotic complications in critically ill patients with COVID-19 was 31% despite systemic thromboprophylaxis, including 27% venous thromboembolisms and 4% arterial thrombotic events.[@bib6] Arterial thromboembolic complications may have devastating consequences, including limb loss, premature intubation, multi-organ dysfunction, stroke, and death.

The purpose of this study was to review the incidence, clinical presentation, management and outcomes with 46 consecutive cases with acute arterial thrombosis in patients with confirmed COVID-19.

Methods {#sec2}
=======

A study was conducted at 7 hospitals within Northwell Health, the largest academic health system in New York State, serving approximately 11 million persons. All patients with confirmed COVID-19 infection and acute arterial thrombosis from March 1, 2020 to May 15, 2020 were entered into a RedCap electronic data capture tools hosted at Northwell Health.[@bib7] These patients were identified based on retrospective review of prospectively maintained database of all in-hospital consultations. REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. The Northwell Health Institutional Review Board approved this case series as minimal-risk research using data collected for routine clinical practice and waived the requirement for informed consent.

Data collected included patient demographic information, comorbidities, anatomical location and clinical presentation of thromboembolism, treatment, and clinical outcomes. Race and sex data were collecte4d by self-report in prespecified fixed categories. The *Northwell COVID survival calculator* was utilized to assess for expected mortality. This tool was constructed using multivariate regression with L1 regularization (LASSO) to predict survival during hospitalization, based on outcomes of 5,233 COVID-19 patients hospitalized at Northwell Health. Patient age, serum blood urea nitrogen, Emergency Severity Index, red cell distribution width, absolute neutrophil count, serum bicarbonate, and glucose were identified as the optimal predictors of survival by multivariate LASSO regression.[@bib8]

All statistics were performed as a descriptive analysis. Continuous variables were expressed as medians and interquartile ranges. Categorical variables were summarized as counts and percentages.

Results {#sec3}
=======

During the study period, Northwell Health System cared for 12,630 hospitalized patients with COVID-19. The initial characteristics of 5700 patients from Northwell are presented elsewhere.[@bib9] This case series presents in-depth results on 49 patients with acute arterial thromboembolisms and COVID-19 were not presented in that article. The median age was 67 years and 76% were men. ([Table 1](#tbl1){ref-type="table"} ) Based on Northwell COVID-19 survival calculator, median predicted mortality at the time of vascular evaluation was 37% (IQR=11-94). Thirteen patients (27%) were severely ill and were intubated prior to onset of ischemia. The median D-dimer level was 2673 (IQR=723-7139) and 83% of patients had D-dimer above 1,000ng/ml. Twenty-two (45%) patients presented with signs of acute arterial ischemia and were subsequently diagnosed with COVID-19. Twenty-seven patients (55%) developed ischemia during hospitalization after an average of 6±4.5 days.Table 1Demographics and Comorbidities[∗](#tbl1fnlowast){ref-type="table-fn"}CharacteristicsN=49 (%)Median age (IQR), year67 (58-75)Gender (%male), n (%)37 (76)Race, n (%) Caucasian17 (35) African American9 (18) Hispanic17 (35) Asian6 (12)Median BMI (IQR), kg/m^2^28(25-32)Comorbidities, n (%)Hypertension26 (53) Diabetes mellitus17 (35) Chronic obstructive pulmonary disease3 (6) Heart disease8 (16) Chronic kidney disease2 (4) Hypercholesterolemia12 (24) Peripheral vascular disease2 (4) Atrial Fibrillation7 (14) Smoking9 (18) active smokers2 (4) ex-smokers7 (14) Malignancy7 (14) Multiple comorbidities22 (45) No past medical history13 (27)Home medications Antiplatelets14 (29) Anticoagulants7 (14)[^1][^2]

The distribution of ischemia included upper (14%) and lower (71%) extremity, mesenteric (4%) and cerebral (10%). Six patients (12%) had concomitant arterial thrombus in multiple anatomic locations. ([Table 2](#tbl2){ref-type="table"} ) Sixteen percent had concomitant deep vein thrombosis. Computed tomography angiogram (CTA) was diagnostic in 25 patients (51%) and duplex ultrasound in 19 (39%). The remining 5 patients were too unstable for transport to imaging and the diagnosis was based on clinical signs of acute ischemia.Table 2Symptoms and anatomic location of the thromboembolism[∗](#tbl2fnlowast){ref-type="table-fn"}Symptoms and location of arterial occlusionN (%)Lower extremity ischemia35 (71) Aortoiliac8/35 (23) Femoral-above knee12/35 (34) popliteal-below knee15/35 (43)Upper extremity ischemia7 (14) Upper arm (subclavian, axillary, brachial)4/7 (57) Forearm (ulnar, radial)3/7 (43)SMA thrombosis with bowel ischemia2 (4)Renal artery thrombosis5 (10)Splenic artery thrombosis3 (6)CVA with carotid artery thrombosis5 (10)Asymptomatic with thoracic aortic thrombus1 (2)Thrombosis in multiple locations[†](#tbl2fndagger){ref-type="table-fn"}6 (12)[^3][^4]

Of the 35 patients with lower extremity ischemia, 9 received open thrombectomy, 2 endovascular thrombectomy and 5 primary amputations. Of the 2 patients with mesenteric ischemia, 1 underwent open thrombectomy and 1 endovascular thrombolysis. A total of 28 patients (57%) were treated with systemic anticoagulation, 3 (7%) received a single weight-based dose of recombinant tissue plasminogen activator (tPA), of those 19 (61%) were deemed too unstable for surgical interventions.

The rate of limb loss was 18% and overall, in-hospital mortality was 46%. Mortality in patients with lower limb ischemia was 50% and in patients with mesenteric ischemia it was 100%. Twenty-five patients (51%) were successfully discharged from hospital and 3 (6%) remain hospitalized at the time this manuscript was prepared.

Discussion {#sec4}
==========

Severe acute respiratory syndrome coronaviruses are an emerging and reemerging source of global pandemic (e.g. SARS, Middle East Respiratory Syndrome, and COVID-19) which have caused significant morbidity and mortality, most notably in the last several months. Although the typical presentation involves viral pneumonia with severe respiratory deterioration,[@bib4] abnormal coagulation occurs in many patients with COVID-19 population and is a predictor of worse prognosis[@bib1] ^,^ [@bib5] ^,^ [@bib10] ^,^ [@bib11] Furthermore, COVID-19 may predispose to both arterial and venous thromboembolic complications.[@bib6] ^,^ [@bib12], [@bib13], [@bib14] To our knowledge, this report represents the largest case series of acute arterial ischemic complications in patients with COVID-19 to date. Out of 12,630 patients that were hospitalized in our system with COVID-19, 49 patients were diagnosed with acute arterial ischemia and 16% of them had concipient venous thromboembolisms. Acute arterial ischemic events were noted as the presenting symptom in 45% of our patients suggesting that, a diagnosis of COVID-19 should be considered in any patient presenting with arterial ischemia. It remains unclear if any of the thromboembolic events in our series were a result of paradoxical embolism in the setting of a patent foramen ovale. The routine use of echocardiography with agitated saline was avoided, due to the concern for aerosolization of the virus.

Our patients were predominantly males over the age of 65 with multiple comorbidities which is compatible to other reports from China and the US,[@bib9] ^,^ [@bib15] which demonstrated increase prevalence of severe COVID-19 infection and worse outcomes in this subset of patients. The overall mortality in our cohort was significantly higher (46%) as compare to 21-26% reported in other studies of hospitalized patients with COVID-19.[@bib9] ^,^ [@bib15] We also observed worse outcomes in patients with acute lower limb ischemia with mortality of 50% as compared to 5%-9% reported in a non-COVID-19 population.[@bib16] ^,^ [@bib17] Mortality from acute mesenteric ischemia is between 22% and 50%,[@bib18], [@bib19] far lower than the 100% rate observed in our series. Although, it is difficult to draw any meaningful conclusions based on our data due to very small sample size. This difference in mortality further supports the fact that hypercoagulable state in patients with SARS-COV-2 is a predictor of worse prognosis.

Inflammation secondary to viral infection has been a key component leading to a pro-coagulant state; this phenomenon is secondary to a myriad of factors including tissue factor-dependent activation of the coagulation cascade secondary to endothelial cell injury and dysfunction, elevated levels of von Willebrand factor, and toll-like receptor activation of pro-inflammatory cytokines.[@bib20] Historically, SARS-CoV-1 and MERS-CoV also exhibited similar prothrombotic complications, as well as thrombocytopenia.[@bib21] Furthermore, disseminated intravascular coagulation (DIC) was a prevalent complication in many of the fatal MERS-CoV cases.[@bib22] Many patients with COVID-19 infection present with thrombocytopenia and elevated D-dimer levels, which are augmented in the most severe forms of the disease.[@bib23] Non-survivors of COVID-19 have been shown to have higher D-dimer and fibrin degradation product levels, with longer prothrombin times, associated with coagulation dysfunction. In our cohort, all patients had elevated D-dimer levels and 83% of patients had D-dimer above 1,000ng/ml. We observed 77% mortality in patients with d-dimer levels over 5,000ng/ml. Elevated D-dimer levels reiterate the acquired hypercoagulability in these patients as well as inflammatory state. With further research, these levels may help to predict which patients with COVID-19 will develop thromboembolic complications, and subsequently worse outcomes.

Previous coronavirus and influenza epidemics have suggested that viral infections can trigger acute coronary syndromes, arrhythmias, and exacerbation of heart failure.[@bib24], [@bib25] Huang and et al. reported 12% incidence of acute cardiac injury in patients with COVID-19. In this series, 16% of patients had preexisting cardiac disease and 14% had history of arrhythmias. Given the baseline cardiovascular disease, the development of arrhythmias, and the hypercoagulable states in patients with SARS-CoV-2 infection, the potential to develop thromboembolic disease is understandably high.

Limitations {#sec4.1}
-----------

This study has several limitations. It is a retrospective descriptive review with no direct comparison with patients without COVID-19 infection (control group). We were not able to investigate a direct cause-effect mechanism and that was not the intention of this review. With the limited number of cases, it is also difficult to assess risk factors for disease distribution and outcomes. Also, some patients remained in the hospital and the outcomes were unknown at the time of data cutoff. Finally, this series is likely an under representation of the true incidence of acute arterial thromboembolic events in patients with COVID-19, as both asymptomatic cases, and acute arterial ischemic events in moribund patients were likely never diagnosed.

Conclusion {#sec5}
==========

In this series of patients with COVID-19 and acute arterial ischemia, presentation varied from asymptomatic to non-salvageable. Prognosis was largely driven by the overall physiologic condition of the patient at presentation and also by duration of symptoms and was generally poor. Limb loss rate was high at 18% and overall mortality was 46%. Eighty-three percent of patients had elevated d-dimer levels above 1,000ng/ml. In patients with COVID-19, hypercoagulability is likely related to an inflammatory cascade with cytokine storm secondary to sepsis, possible disseminated intravascular coagulation, and excessive activation of the coagulation cascade. Arterial thromboembolic complications carry a devastating consequences of limb loss, multi-organ dysfunction and death. A diagnosis of COVID-19 should be considered in any patient presenting with arterial ischemia.
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[^1]: Race and ethnic group were reported by the patient or were determined by family or physician if patient was non-communicative.

[^2]: Percentages may not total 100 because of rounding. IQR denotes interquartile range.

[^3]: Percentages may not total 100 because of rounding.

[^4]: concomitant thrombus in the SMA, renal arteries, lower and upper extremity arteries. SMA denotes superior mesenteric artery and CVA cerebrovascular accident.
